217 related articles for article (PubMed ID: 22935031)
1. The role of PML ubiquitination in human malignancies.
Chen RH; Lee YR; Yuan WC
J Biomed Sci; 2012 Aug; 19(1):81. PubMed ID: 22935031
[TBL] [Abstract][Full Text] [Related]
2. SCP phosphatases suppress renal cell carcinoma by stabilizing PML and inhibiting mTOR/HIF signaling.
Lin YC; Lu LT; Chen HY; Duan X; Lin X; Feng XH; Tang MJ; Chen RH
Cancer Res; 2014 Dec; 74(23):6935-46. PubMed ID: 25293974
[TBL] [Abstract][Full Text] [Related]
3. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
[TBL] [Abstract][Full Text] [Related]
4. CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Choi S; Baldini C; Konstantinidou G; Pandolfi PP
Mol Cell Biochem; 2008 Sep; 316(1-2):149-54. PubMed ID: 18566754
[TBL] [Abstract][Full Text] [Related]
5. SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome.
Cao X; Clavijo C; Li X; Lin HH; Chen Y; Shih HM; Ann DK
Mol Cancer Ther; 2008 Apr; 7(4):923-34. PubMed ID: 18413806
[TBL] [Abstract][Full Text] [Related]
6. E6AP promotes the degradation of the PML tumor suppressor.
Louria-Hayon I; Alsheich-Bartok O; Levav-Cohen Y; Silberman I; Berger M; Grossman T; Matentzoglu K; Jiang YH; Muller S; Scheffner M; Haupt S; Haupt Y
Cell Death Differ; 2009 Aug; 16(8):1156-66. PubMed ID: 19325566
[TBL] [Abstract][Full Text] [Related]
7. The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1.
Mathieu MG; Miles AK; Ahmad M; Buczek ME; Pockley AG; Rees RC; Regad T
Cell Death Dis; 2014 Feb; 5(2):e1061. PubMed ID: 24525737
[TBL] [Abstract][Full Text] [Related]
8. AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.
Li Q; He Y; Wei L; Wu X; Wu D; Lin S; Wang Z; Ye Z; Lin SC
Oncogene; 2011 Mar; 30(10):1194-204. PubMed ID: 21057547
[TBL] [Abstract][Full Text] [Related]
9. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network.
Song MS; Salmena L; Carracedo A; Egia A; Lo-Coco F; Teruya-Feldstein J; Pandolfi PP
Nature; 2008 Oct; 455(7214):813-7. PubMed ID: 18716620
[TBL] [Abstract][Full Text] [Related]
10. The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein.
Guan D; Factor D; Liu Y; Wang Z; Kao HY
Oncogene; 2013 Aug; 32(33):3819-28. PubMed ID: 22945642
[TBL] [Abstract][Full Text] [Related]
11. Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis.
Hayakawa F; Abe A; Kitabayashi I; Pandolfi PP; Naoe T
J Biol Chem; 2008 Sep; 283(36):24420-5. PubMed ID: 18621739
[TBL] [Abstract][Full Text] [Related]
12. β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.
Satow R; Shitashige M; Jigami T; Fukami K; Honda K; Kitabayashi I; Yamada T
Gastroenterology; 2012 Mar; 142(3):572-81. PubMed ID: 22155184
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment.
Wang YT; Chen J; Chang CW; Jen J; Huang TY; Chen CM; Shen R; Liang SY; Cheng IC; Yang SC; Lai WW; Cheng KH; Hsieh TS; Lai MZ; Cheng HC; Wang YC; Chen RH
J Clin Invest; 2017 Aug; 127(8):2982-2997. PubMed ID: 28691927
[TBL] [Abstract][Full Text] [Related]
14. The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.
Rabellino A; Carter B; Konstantinidou G; Wu SY; Rimessi A; Byers LA; Heymach JV; Girard L; Chiang CM; Teruya-Feldstein J; Scaglioni PP
Cancer Res; 2012 May; 72(9):2275-84. PubMed ID: 22406621
[TBL] [Abstract][Full Text] [Related]
15. E2FBP1 antagonizes the p16(INK4A)-Rb tumor suppressor machinery for growth suppression and cellular senescence by regulating promyelocytic leukemia protein stability.
Fukuyo Y; Takahashi A; Hara E; Horikoshi N; Pandita TK; Nakajima T
Int J Oral Sci; 2011 Oct; 3(4):200-8. PubMed ID: 22010578
[TBL] [Abstract][Full Text] [Related]
16. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.
Lallemand-Breitenbach V; Jeanne M; Benhenda S; Nasr R; Lei M; Peres L; Zhou J; Zhu J; Raught B; de Thé H
Nat Cell Biol; 2008 May; 10(5):547-55. PubMed ID: 18408733
[TBL] [Abstract][Full Text] [Related]
17. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR.
Bernardi R; Guernah I; Jin D; Grisendi S; Alimonti A; Teruya-Feldstein J; Cordon-Cardo C; Simon MC; Rafii S; Pandolfi PP
Nature; 2006 Aug; 442(7104):779-85. PubMed ID: 16915281
[TBL] [Abstract][Full Text] [Related]
18. CK2 and PML: regulating the regulator.
Lallemand-Breitenbach V; de Thé H
Cell; 2006 Jul; 126(2):244-5. PubMed ID: 16873055
[TBL] [Abstract][Full Text] [Related]
19. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
[TBL] [Abstract][Full Text] [Related]
20. MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs.
Peche LY; Scolz M; Ladelfa MF; Monte M; Schneider C
Cell Death Differ; 2012 Jun; 19(6):926-36. PubMed ID: 22117195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
